金吾财讯 | 创新实验室服务巨头徕博科(LH)宣布，正式推出扩展版DPYD基因分型检测服务。该检测旨在化疗开始前，精确识别出对氟尿嘧啶类化疗药物具有高严重性、甚至致命性副作用风险的癌症患者，标志着个体化精准医疗在肿瘤治疗领域的进一步深化。公告显示，升级后的检测现已全面覆盖分子病理学协会(AMP)推荐的所有1级和2级DPYD基因变异体，完全符合美国食品药品监督管理局(FDA)、美国国家综合癌症网络(NCCN)以及临床药物基因组学实施财团(CPIC)的最新权威指南。目前，该检测已正式面向各大医疗机构与临床医生开放。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.